振源胶囊联合美托洛尔治疗冠心病心绞痛的临床研究

目的探讨振源胶囊联合琥珀酸美托洛尔缓释片治疗冠心病心绞痛的临床疗效。方法选取2019年4月—2020年10月南阳市中心医院收治的85例冠心病心绞痛患者,按照随机数字表法将85例患者分为对照组(42例)和治疗组(43例)。对照组口服琥珀酸美托洛尔缓释片,1片/次,1次/d。治疗组在对照组治疗的基础上口服振源胶囊,0.5g/次,3次/d。两组患者连续治疗1个月。考察两组心绞痛、心电图的疗效,并比较两组患者的心绞痛发作次数、每次持续时间、疼痛程度和血清因子水平。结果治疗后,治疗组的心绞痛总有效率(93.02%)高于对照组(76.19%)(P0.05)。治疗后,治疗组的心电图总有效率(81.40%)高于对照组(61.90%)(P0.05)。治疗后,两组的心绞痛发作次数、每次持续时间、视觉模拟评分法(VAS)评分明显降低(P0.05),且治疗组发作次数、每次持续时间、VAS评分降低的更多(P0.05)。治疗后,两组的丙二醛(MDA)、脊髓内髓过氧化物酶(MPO)水平显著降低,超氧化物歧化酶(SOD)水平显著升高(P0.05);治疗后,治疗组的MDA、MPO水平比对照组低,SOD水平比对照组高(P0.05)。结论振源胶囊联合琥珀酸美托洛尔缓释片可提高冠心病心绞痛的临床疗效,有效减轻心绞痛症状,减轻氧化反应。

Clinical study on Zhenyuan Capsules combined with metoprolol in treatment of angina pectoris of coronary heart disease

Objective To investigate the clinical effect of Zhenyuan Capsules combined with Metoprolol Succinate Sustained-release Tablets in treatment of angina pectoris of coronary heart disease. Methods Patients (85 cases) with angina pectoris of coronary heart disease in Nanyang Central Hospital from April 2019 to October 2020 were randomly divided into the control group (42 cases) and the treatment group (43 cases). Patients in the control group were po administered with Metoprolol Succinate Sustained-release Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Zhenyuan Capsules on the basis of the control group, 0.5 g/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the curative effect of angina pectoris and the ECG curative effect were evaluated, and the frequency and duration of angina pectoris, the degree of pain and the level of serum factors in two groups were compared. Results After treatment, the total effective rate of angina pectoris in the treatment group (93.02%) was higher than that in the control group (76.19%) (P<0.05). After treatment, the ECG curative effect in the treatment group (81.40%) was higher than that in the control group (61.90%) (P<0.05). After treatment, the frequency and duration of angina pectoris and the VAS score of two groups were significantly decreased (P<0.05), and the frequency and duration of angina pectoris and the VAS score of the treatment group were lower than those in the control group (P<0.05). After treatment, the levels of MDA and MPO in two groups were significantly decreased, but the level of SOD in two groups was significantly increased (P<0.05). After treatment, the levels of MDA and MPO in the treatment group were lower than those in the control group, but the level of SOD in the treatment group was higher than that in the control group (P<0.05). Conclusion Zhenyuan Capsules combined with Metoprolol Succinate Sustained-release Tablets can improve the clinical efficacy of angina pectoris, reduce the symptoms and oxidation reaction.